Cancer clinical trials in the region Île-de-France
787 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Lymphoma
CLL & Richter's syndrome
#NCT05006716
Required histologic types
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Richter's syndrome
Required histologic sub types
Large B cell lymphoma
Mantel cell lymphoma
Follicular lymphoma
Marginal zone lymphoma
Waldenström lymphoma
Lymphocytic lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
9 recruiting sites
BeOne Medecines
Phase 1 / Phase 2
Breast cancer
#NCT04585750
#2023-504251-27-00
Phase 2 cohorte de cancer du sein
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
Other KRAS
KRAS G12C
KRAS G12D
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
#NCT04585750
#2023-504251-27-00
Phase 2 autres tumeurs solides
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
Other KRAS
KRAS G12C
KRAS G12D
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Endometrial cancer
#NCT04585750
#2023-504251-27-00
Phase 2 cohorte de patients atteints d'un cancer de l'endomètre
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
Other KRAS
KRAS G12C
KRAS G12D
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Lung cancer
#NCT04585750
#2023-504251-27-00
Phase 2 cohorte de patients atteints de cancer du poumon
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
KRAS G12C
KRAS G12D
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT04585750
#2023-504251-27-00
Phase 2 cohorte de patientes atteintes d'un cancer de l'ovaire
Required histologic types
Epithelial ovarian cancer
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Prostate cancer
#NCT07190300
#2025-521873-15-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Internal Vectorised Radiotherapy (IVR)
3 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2
Stomach and esophageal cancer
#NCT06445972
#2023-509306-29-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2
Stomach and esophageal cancer
#NCT06469944
#2023-509307-33-00
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Antibody Drug Conjugates (ADC)
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2
Pancreas cancer
Stomach and esophageal cancer
#NCT06005493
#2023-000154-20
Required histologic types
Stomach
Oesogastric junction
Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
AstraZeneca